期刊文献+

氯法拉滨在血液系统恶性肿瘤治疗中的应用 被引量:2

原文传递
导出
摘要 急性白血病是儿童以及成人常见的血液恶性肿瘤之一,近年来由于支持治疗以及化疗方案的改进,在儿童急性淋巴细胞白血病(ALL)5年无病生存(DFS)率达80%以上,急性髓系白血病(AML)5年DFS率达40%,成人ALL患者长期生存率则低于30%。
作者 路瑾 黄晓军
出处 《中华血液学杂志》 CAS CSCD 北大核心 2010年第1期66-68,共3页 Chinese Journal of Hematology
  • 相关文献

参考文献23

  • 1Faderl S, Gandhi V, Keating MJ, et al. The role of clofarabine in hematologic and solid malignancies-development of a next-generation nucleoside analog. Cancer, 2005,103 : 1985-1995.
  • 2King KM, Damaraju VL, Vickers MF, et al. A comparison of the transportability, and its role in cytotoxicily, of elofarabitle, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol,2006, 69:346-353.
  • 3Zhang Y, Zhang J, Shahriar M, et al. Clofarabine induces hypomethylation of DNA and expression of cancer-testis antigens. Blood, 2008,112 : absract 379.
  • 4Gandhi V, Kantarjian H, Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res, 2003, 9:6335-6342.
  • 5Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is aetive in pediatric patients with advaneed leukemia. Blood, 2004,103:784-789.
  • 6Kantarjian HM, Gandhi V, Kozueh P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol, 2003, 21 : 1167-1173.
  • 7Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarahine in patients with refractory or relapsed acute leukemia. Blood, 2003,102:2379-2386.
  • 8Jeha S, Gaynon PS, Razzouk BI, et al. Phase Ⅱ study of elofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol, 2006,24: 1917-1923.
  • 9Faded S, Gandhi V, O' Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with evtarabine (ara-C) in relapsed and refraetory acute leukemias. Blood, 2005,105: 940- 947.
  • 10Becker PS, Estey E, Petersdorf S, et al. Phase Ⅰ trial of clofarabine and high dose cytarabine with G-CSF priming (G-CLAC) for relapsed or refractory acute myeloid leukemia. Blood, 2005, 112 : absract 2964.

同被引文献35

  • 1夏敏,蒋慧.儿童急性白血病治疗新药氯法拉滨[J].世界临床药物,2007,28(6):356-359. 被引量:11
  • 2Pui CH, Jeha S, Kirkpatrick P. Clofarabine [ J]. Nat Rev Drug Discov, 2005, 4 (5) : 369-370.
  • 3Tallman MS. New agents for the treatment of acute myeloid leukemia [ J ]. Best Pract Res Clin Haematol, 2006, 19 (2) : 311- 320.
  • 4Lindemalm S, Liliemark J, Juliusson G, et al. Cytotoxieity and pharmacokineties of eladribine metabolite, 2-ehloroadenine in patients with leukemia [J]. Cancer Lett, 2004, 210 ( 2 ) : 171- 177.
  • 5Zhenchuk A, Lotfi K, Juliusson G, et al. Mechanisms of anticancer action and pharmacology of clofarabine [ J ]. Biochem Pharmacol, 2009, 78(11 ): 1351-1359.
  • 6Bonate PL, Arthaud L, Cantrell WR Jr, et al. DiscovexT and development of clofarabine: a nueleoside analogue for treating cancer [J]. Nat Rev Drug Discov, 2006, 5(10): 855-863.
  • 7Reichelova V, Liliemark J, Albertioni F, et al. Liquid chromatographic study of acid stability of 2-chloro-2'-arabino- fluoro- 2'-deoxyadenosine, 2-chloro-2'-deoxyadenosine and related analogues [ J].J Pharm Biomed Anal, 1995, 13 (4-5) : 711-714.
  • 8Xie C, Plunkett W. Metabolism and actions of 2-ehloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)-adenine in human lymphoblastoid cells[J]. Cancer Res, 1995, 55(13): 2847-2852.
  • 9King KM, Damaraju VL, Vickers MF, et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems [Jl. Mol Pharmacol, 2006, 69 ( 1 ) : 346-353.
  • 10Chen LS, Plunkett W, Gandhi V. Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues [ J ]. Leuk Res, 2008, 32(10) : 1573-1581.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部